Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
FYI: The Biotech group managed to rally 18% off its February lows, but it’s worth pointing out that over the last couple of weeks, it has begun to roll over again. Below is a chart of the iShares Nasdaq Biotech ETF (IBB) over the last five years. After surging for multiple years from late 2011 through mid-2015, the group has been a serial underperformer and is down 33% since peaking last July. Unlike the Energy sector, which has managed to break above the top of its downtrend channel, Biotech remains stuck in a nasty downtrend. Regards, Ted https://www.bespokepremium.com/think-big-blog/biotech-remains-stuck-in-downtrend/
